Application of curcumin to heart failure therapy by targeting transcriptional pathway in cardiomyocytes

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 1, 2013, Pages 13-17

  Katanasaka, Yasufumi ^a,b   Sunagawa, Yoichi ^a,b   Hasegawa, Koji ^b   Morimoto, Tatsuya ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Cardiomyocyte; Curcumin; GATA4; Heart failure therapy; p300; Transcription

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CURCUMIN; CYCLIN DEPENDENT KINASE 9; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; E1A ASSOCIATED P300 PROTEIN; ENALAPRIL; MINERALOCORTICOID ANTAGONIST; THERACURCUMIN; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG;

CURCUMA LONGA; DRUG BIOAVAILABILITY; DRUG METABOLISM; HEART DEVELOPMENT; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MONOTHERAPY; NANOPHARMACEUTICS; NONHUMAN; REVIEW; SYSTOLIC HEART FAILURE; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; CURCUMIN; ENZYME INHIBITORS; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; TRANSCRIPTION, GENETIC;

EID: 84872737786     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b212022     Document Type: Review

References (56)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol., 65, 45-79 (2003).
2. Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ. Res., 92, 1079-1088 (2003).
3. MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu. Rev. Physiol., 62, 289-319 (2000).
4. Miyamoto S, Kawamura T, Morimoto T, Ono K, Wada H, Kawase Y, Matsumori A, Nishio R, Kita T, Hasegawa K. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation, 113, 679-690 (2006).
5. Morimoto T, Sunagawa Y, Fujita M, Hasegawa K. Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin. Circ. J., 74, 1059-1066 (2010).
6. Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? Trends Mol. Med., 18, 138-144 (2012).
7. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer, 10, 12 (2011).
8. Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci. Ther., 16, 285-297 (2010).
9. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curcumin": from kitchen to clinic. Biochem. Pharmacol., 75, 787-809 (2008).
10. D eodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res., 71, 632-634 (1980).
11. Taylor RA, Leonard MC. Curcumin for inflammatory bowel disease: a review of human studies. Altern. Med. Rev., 16, 152-156 (2011).
12. Srivastava G, Mehta JL. Currying the heart: curcumin and cardioprotection. J. Cardiovasc. Pharmacol. Ther., 14, 22-27 (2009).
13. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol., 133, 145-151 (2009).
14. Paradis P, MacLellan WR, Belaguli NS, Schwartz RJ, Schneider MD. Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. J. Biol. Chem., 271, 10827-10833 (1996).
15. Takaya T, Kawamura T, Morimoto T, Ono K, Kita T, Shimatsu A, Hasegawa K. Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes. J. Biol. Chem., 283, 9828-9835 (2008).
16. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW Jr, Izumo S, Markham BE. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc. Natl. Acad. Sci. U.S.A., 94, 7543-7548 (1997).
17. N akagawa Y, Kuwahara K, Harada M, Takahashi N, Yasuno S, Adachi Y, Kawakami R, Nakanishi M, Tanimoto K, Usami S, Kinoshita H, Saito Y, Nakao K. Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes. J. Mol. Cell. Cardiol., 41, 1010-1022 (2006).
18. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res., 63, 467-475 (2004).
19. Xing W, Zhang TC, Cao D, Wang Z, Antos CL, Li S, Wang Y, Olson EN, Wang DZ. Myocardin induces cardiomyocyte hypertrophy. Circ. Res., 98, 1089-1097 (2006).
20. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol., 7, 589-600 (2006).
21. Leenders JJ, Pinto YM, Creemers EE. Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling. J. Mol. Cell. Cardiol., 51, 156-167 (2011).
22. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation, 96, 3943-3953 (1997).
23. Kakita T, Hasegawa K, Morimoto T, Kaburagi S, Wada H, Sasayama S. p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene. J. Biol. Chem., 274, 34096-34102 (1999).
24. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Masutani H, Kitsis RN, Matsumori A, Sasayama S. GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the beta-myosin heavy chain gene in cardiac myocytes. J. Biol. Chem., 274, 12811-12818 (1999).
25. Shiojima I, Komuro I, Oka T, Hiroi Y, Mizuno T, Takimoto E, Monzen K, Aikawa R, Akazawa H, Yamazaki T, Kudoh S, Yazaki Y. Context-dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx-2.5 and GATA-4. J. Biol. Chem., 274, 8231-8239 (1999).
26. Belaguli NS, Sepulveda JL, Nigam V, Charron F, Nemer M, Schwartz RJ. Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Mol. Cell. Biol., 20, 7550-7558 (2000).
27. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C, Leiden JM. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev., 11, 1048-1060 (1997).
28. Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD, Orkin SH. Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors. Genes Dev., 15, 839-844 (2001).
29. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J. Biol. Chem., 276, 30245-30253 (2001).
30. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, Sasayama S. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J. Biol. Chem., 275, 13721-13726 (2000).
31. L iang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol. Cell. Biol., 21, 7460-7469 (2001).
32. Morimoto T, Hasegawa K, Wada H, Kakita T, Kaburagi S, Yanazume T, Sasayama S. Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes. J. Biol. Chem., 276, 34983-34989 (2001).
33. Yanazume T, Hasegawa K, Wada H, Morimoto T, Abe M, Kawamura T, Sasayama S. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J. Biol. Chem., 277, 8618-8625 (2002).
34. Hirai M, Ono K, Morimoto T, Kawamura T, Wada H, Kita T, Hasegawa K. FOG-2 competes with GATA-4 for transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. J. Biol. Chem., 279, 37640-37650 (2004).
35. Yanazume T, Hasegawa K, Morimoto T, Kawamura T, Wada H, Matsumori A, Kawase Y, Hirai M, Kita T. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol., 23, 3593-3606 (2003).
36. Sunagawa Y, Morimoto T, Takaya T, Kaichi S, Wada H, Kawamura T, Fujita M, Shimatsu A, Kita T, Hasegawa K. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J. Biol. Chem., 285, 9556-9568 (2010).
37. Wei JQ, Shehadeh LA, Mitrani JM, Pessanha M, Slepak TI, Webster KA, Bishopric NH. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation, 118, 934-946 (2008).
38. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet., 10, 32-42 (2009).
39. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem., 279, 51163-51171 (2004).
40. Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neckers L. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem., 2, 169-174 (2006).
41. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest., 118, 868-878 (2008).
42. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ. J., 75, 2151-2159 (2011).
43. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm., 4, 807-818 (2007).
44. Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int. J. Pharm., 360, 219-224 (2008).
45. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, Oku N. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int. J. Cancer, 127, 2685-2698 (2010).
46. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J. Biomed. Mater. Res. A, 86, 300-310 (2008).
47. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol., 32, 1119-1123 (2008).
48. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol., 79, 330-338 (2010).
49. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm., 6, 928-939 (2009).
50. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev. Res., 4, 1158-1171 (2011).
51. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 34, 660-665 (2011).
52. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, Katanasaka Y, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K, Morimoto T. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats. Biol. Pharm. Bull., 35, 139-144 (2012).
53. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur. Heart J., 25, 1454-1470 (2004).
54. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J., 25, 1341-1362 (2004).
55. Funder J. Mineralocorticoid receptor antagonists for heart failure. Expert Opin. Pharmacother., 12, 2767-2769 (2011).
56. Tamargo J, López-Sendón J. Novel therapeutic targets for the treatment of heart failure. Nat. Rev. Drug Discov., 10, 536-555 (2011).